JP Equity Partners

14/07/2026

A brief look back at the 25 June ‘Boom of the Biotech II’ Investor Briefing at Steves Bar & Cafe

We were pleased to host an engaging session featuring insights from Racura Oncology, TrivarX, and EMVision Medical Devices, supported by our co hosts including Samphire Rottnest and MC Matt Birney of Bulls N' Bears.

Please find a short highlight video below capturing key moments from the event.

06/07/2026

23/06/2026

**LAST CHANCE**
JP Equity Partners' ‘Boom of the Biotech II' Investor Briefing will be held on Thursday, 25th June at Steves Bar & Cafe.

Join us for drinks and canapes and hear insights from Racura Oncology, TrivarX, and EMVision Medical Devices, presented by Matt Birney.

REGISTER HERE: https://tinyurl.com/45fjfjmz

Bulls N' Bears Samphire Rottnest

17/06/2026

** DOOR PRIZE **
JP Equity Partners would like to welcome Samphire Rottnest as a co-host to our 'Boom of the Biotech II' Investor Briefing on Thursday 25th June at Steves Bar & Cafe

SAMPHIRE ROTTNEST has generously donated two nights’ accommodation in a standard room, inclusive of continental breakfast and in‑room champagne as a door prize at our event!

REGISTER HERE: https://tinyurl.com/45fjfjmz

JP Equity Partners 'Boom of the Biotech II' Investor Briefing

11/06/2026

JP Equity Partners is excited to welcome Scott Kirkland, CEO and Managing Director at EMVision Medical Devices Ltd (ASX: EMV) to speak at our ‘Boom of the Biotech II' Investor Briefing on Thursday 25th June at Steves Bar & Cafe.

EMVision Medical Devices is developing a new category of portable brain scanners designed for rapid, accessible point‑of‑care imaging to improve the timely diagnosis and treatment of stroke and other neurological emergencies.

REGISTER HERE: https://tinyurl.com/45fjfjmz

09/06/2026

JP Equity Partners is excited to welcome Dr Danielle Meyrick, Chief Executive Officer at TrivarX (ASX: TRI) to speak at our ‘Boom of the Biotech II' Investor Briefing on Thursday 25th June at Steves Bar & Cafe.

TrivarX Limited is advancing Stabl‑Im, an MRI‑based functional imaging platform using stable isotopes to visualise actively replicating cancer cells without radioactive tracers, enabling earlier and more meaningful insights into tumour activity as it moves toward a Phase 1 study in H2 CY26.

REGISTER HERE: https://tinyurl.com/45fjfjmz

04/06/2026

JP Equity Partners is excited to welcome Dr Daniel Tillett, Managing Director and Chief Executive Officer at Racura Oncology (ASX:RAC) to speak at our ‘Boom of the Biotech II' Investor Briefing on Thursday 25th June at Steves Bar & Cafe.

Racura Oncology is advancing its MYC‑silencing anticancer agent, (E,E)-bisantrene, through multiple clinical programs using its proprietary RC220 formulation, supported by strong IP protection and collaborations with leading global research institutions.

REGISTER HERE: https://tinyurl.com/45fjfjmz

02/06/2026

JP Equity Partners is excited to announce our 'Boom of the Biotech II' Investor Briefing will be held at Steves Bar & Cafe on Thursday, 25th June 2026!

Join us for complimentary drinks and canapes while gaining exclusive insights 3 of the hottest companies in biotech, Racura Oncology, TrivarX, and EMVision Medical Devices Ltd.

REGISTER HERE: https://tinyurl.com/45fjfjmz

JP Equity Partners 'Boom of the Biotech II' Investor Briefing

30/03/2026

A huge thank you to everyone who helped make our ‘Copper in the Age of AI’ Investor Briefing at Steves Bar & Cafe such a standout evening. Norfolk Metals Ltd, Caravel Minerals and Alma Metals delivered valuable insights, supported by our event partner Bulls N' Bears, co hosts including Heliwest, and MC Matt Birney.

The highlight video is now ready!